About: Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $62.65 (+1.13%)
CYTK NASDAQ Cytokinetics Inc
Cytokinetics Inc share price
Atividade de preço de CYTK
Último preço
$ 62,650
Variação (24h)
0,70 USD (1,13%)
Volume
1.91M
Volume (média 4 sem.)
-
Abertura
$ 62,06
Variação do dia
$ 61,84 - $ 63,61
Fechamento anterior
$ 61,95
Último negócio
19 Oct, 8:00 pm GMT+0
Atrasado
19 Oct, 8:00 pm GMT+0
CYTK price performance
Atrasado
19 Oct, 8:00 pm GMT+0
quote.marketSignals